Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy.
Hasumi K1, Aoki Y1, Wantanabe R1, Mann DL2.
Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy.
Hasumi K1, Aoki Y, Watanabe R, Hankey KG, Mann DL.
Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity
Caroline J Voskens, Ryuko Watanabe, Sandra Rollins, Dario Campana, Kenichiro Hasumi and Dean L Mann
Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers.
Mann DL1, Celluzzi CM, Hankey KG, Harris KM, Watanabe R, Hasumi K.
Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy.
Sato T1, Terai M, Yasuda R, Watanabe R, Berd D, Mastrangelo MJ, Hasumi K.